SpringWorks Therapeutics (SWTX) Set to Announce Earnings on Tuesday

SpringWorks Therapeutics (NASDAQ:SWTX) will be announcing its earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.76) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.58. The business had revenue of $59.73 million during the quarter, compared to the consensus estimate of $34.42 million. The business’s revenue for the quarter was up 59732900.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.25) EPS. On average, analysts expect SpringWorks Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

SpringWorks Therapeutics Trading Up 2.7 %

Shares of NASDAQ:SWTX opened at $33.99 on Friday. The firm has a 50 day moving average of $33.26 and a 200-day moving average of $37.48. The stock has a market capitalization of $2.52 billion, a PE ratio of -7.67 and a beta of 0.79. SpringWorks Therapeutics has a 12 month low of $18.00 and a 12 month high of $53.92.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $76.00 target price on shares of SpringWorks Therapeutics in a research note on Wednesday, August 28th. Wedbush reiterated an “outperform” rating and set a $77.00 target price on shares of SpringWorks Therapeutics in a research report on Thursday. Finally, JPMorgan Chase & Co. raised their price objective on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $68.50.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.